Citation Impact
Citing Papers
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
Cancer immunotherapy beyond immune checkpoint inhibitors
2018
Cancer treatment and survivorship statistics, 2022
2022 Standout
Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials
2013 Standout
A view on drug resistance in cancer
2019 StandoutNature
From tumour heterogeneity to advances in precision treatment of colorectal cancer
2016
Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study
2019
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Pancreatic cancer
2020 Standout
The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery
2016
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
2019 Standout
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Cancer stem cells revisited
2017 Standout
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study
2017
A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
2017
Delivery technologies for cancer immunotherapy
2019 Standout
Colorectal cancer
2019 Standout
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
2016
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
2019
High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy
2020 Standout
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
2016
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
2015
Current understanding of the human microbiome
2018 Standout
Engineering and physical sciences in oncology: challenges and opportunities
2017
Oxidative Stress in Cancer
2020 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer
2011
New developments for antibody-drug conjugate-based therapeutic approaches
2016
Management of Side Effects of Androgen Deprivation Therapy
2011
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
2014 Standout
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Biomarker-driven and molecular targeted therapies for colorectal cancers
2017
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
Sorafenib Induced Thyroiditis in Two Patients with Hepatocellular Carcinoma
2011
Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement
2014 Standout
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
2016 Standout
2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum
2017 Standout
Drugs Affecting Thyroid Function
2010
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
2012 Standout
Sunitinib-Induced Thyrotoxicosis Followed by Persistent Hypothyroidism with Shrinkage of Thyroid Volume
2010
Testosterone and obesity
2015
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
2015
Cancer treatment and survivorship statistics, 2016
2016 Standout
Cancer treatment and survivorship statistics, 2019
2019 Standout
Risks of Major Long‐Term Side Effects Associated with Androgen‐Deprivation Therapy in Men with Prostate Cancer
2018
Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
2010
Treatment With Thyroid Hormone
2014
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
2017
Sunitinib-induced thyrotoxicosis - a not so rare entity.
2015
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Jason E. Faris being referenced
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
2016
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer
2010
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C
2017
Sunitinib (Sutent)-Induced Thyrotoxicosis Due to Destructive Thyroiditis: A Case Report
2007
Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas
2015
Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.
2014
TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.
2017
Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer
2015
Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).
2016
MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study.
2014